drugset
drugset / Trial / NCT05706623

A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

NCT05706623 ↗

Phase 1 Completed 16 enrolled VectivBio AG
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to assess the pharmacokinetics (PK) of apraglutide in subjects with hepatic impairment compared with matched control subjects with normal hepatic function following single subcutaneous (SC) dose administration.

Timeline

Start
2023-01-30
Primary completion
2023-04-04
Completion
2023-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Apraglutide Peptide — Subcutaneous

Indications

No indication recorded.